Efficacy and Survival
ADENOID CYSTIC CARCINOMA, SOLID TUMOR
Among all 76 solid tumor patients (including the confirmatory cohort and all patients with ACC), there were 37 (49%) demonstrating SD but no objective responses (Efficacy and survival outcomes for patients with solid tumorAbbreviations: ACC = adenoid cystic carcinoma, CI = confidence interval, NR = not reached, PFS = progression-free survival, OS = overall survival.
Waterfall (At a median follow-up of 5.4 months (range: 0.1–20.5+), median PFS for the entire solid tumor cohort was 1.9 months (95% CI, 1.4–3.2) with a 6-month PFS estimate of 15.5% (95% CI, 7.5–26.0), which was similar across dose-escalation and confirmatory dose cohorts. Among the ACC cohort, median PFS was 2.5 months (95% CI, 1.5–3.7) with a 6-month PFS estimate of 18.6% (95% CI, 7.9–32.8; PFS (